Phase 2 N=30 Contrastim Stroke Trial
Stroke
Primary: Upper Extremity Fugl-Meyer Score — 23.8; 31.5; 31.9; 37 units on a scale — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=406 Dual Diagnosis Inpatients: Telephone Monitoring RCT to Improve Outcomes
Diagnosis, Dual (Psychiatry)
Primary: Readiness to Attend Substance Use Disorder Continuing Care — 1.8; 2.2 units on a scale — p=<.05
Phase 2 N=640 Promoting Tolerance to Peanut in High-Risk Children
Eczema · Egg Allergy · Food Allergy
Primary: Number of Participants With Peanut Allergy at 60 Months of Age - by Skin Prick Test Stratum — 36; 5; 18; 5 Participants — p=<0.0001
Phase 2 N=18 Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Venous Thromboembolism
Primary: Plasma Concentration of Total Dabigatran (SUM BIBR 953 ZW) — 79.4; 90.6; NA; 129.0 ng/mL
Phase 2 N=20 A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)
Carcinoma, Non-small-cell Lung
Primary: Phase I: Number of Participants Experiencing at Least One Dose-Limiting Toxicity (DLT) Adverse Event (AE) During the First Four Weeks of Dalotuzumab Plus Erlotinib…
Phase 2 N=36 A Study of the GI Sleeve for the Treatment of Type 2 Diabetes
Type 2 Diabetes
Primary: Change in HbA1c Values From Baseline Measurement — 2.4; 2.2; 0.8; 1.6 percentage of HbA1c
Phase 2 N=22 Study for Pre-Surgical Weight Loss in Type II Diabetes Patients
Type 2 Diabetes · Obesity
Primary: % of Excess Weight Loss (EWL) — 37.7 % excess weight loss
Phase 2 N=72 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Myxofibrosarcoma · Recurrent Adult Soft Tissue Sarcoma · Recurrent Leiomyosarcoma
Primary: The Primary Endpoint for This Trial Was the Percent of Confirmed Tumor Responses. Confirmed Tumor Response to Treatment Was Defined as a Complete or Partial Response(Per…
Phase 2 N=558 Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
Metastatic Colorectal Cancer
Primary: Overall Survival (OS) — 10.8; 11.6; 14.0 Months — p=0.06
Phase 2 N=20 GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Neoplasms, Oral · Mouth Neoplasms
Primary: Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After…
Phase 2 N=84 S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
Lung Cancer
Primary: Overall Survival — 21 months
Phase 2 N=22 Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)
Graft-Versus-Host Disease
Primary: Phase I: Maximum Tolerated Dose (MTD) in Milligrams — 5 MTD of oral LBH589 in milligrams
Phase 2 N=76 Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Prostate Cancer
Primary: Number of Participants With Adverse Events — 19; 22; 19; 16 participants
Phase 2 N=174 Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma
Asthma
Primary: Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14) — 0.3196; 0.3076; 0.2795; 0.2726 Liters — p=<0.0001
Phase 2 N=23 Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Pemphigus
Primary: Number of Patients Achieving a Short- and Long-term Remission of Pemphigus — 23 Participants